Cross-Functional Alignment for EU Access
The new EU HTA Regulation is often described as a technical shift: new methodologies, new assessment structures, and new evidence expectations. But in reality, it represents something far bigger: an organizational shift.
Success under the JCA depends on early alignment across clinical, regulatory, and access functions, to ensure timely readiness for both EMA MAA and JCA as timelines are parallel without option to push the HTA piece out.
In brief:The EU HTA Regulation turns HTA readiness into an operating model question—not a last-mile market access task. Because JCA work runs in parallel with the MAA, misalignment on comparators, endpoints, and evidence narrative can’t be “fixed later” without real cost and delay. The cross‑functional governance, roles, and decision rhythm biotechs need turn the JCA into coordinated execution—and an opportunity to strengthen the evidence package, not a scramble.
Why HTA Is No Longer a “Market Access Function”
For years, HTA was treated as something that happened after regulatory approval, in the domain of market access teams and health economists. It sat downstream of clinical development and operated with little influence over trial design.
That world should be gone.Today, HTA decisions hinge on study design, comparator choice, endpoint selection, and evidence generation strategy — all decisions made far upstream. If HTA isn’t part of early planning, it becomes nearly impossible to fix things later without major cost, time, or operational disruption.
HTA has always influenced clinical, regulatory, medical, and access decisions, but many organizations treated it as a downstream activity. Under the new EU system, that separation is no longer viable: if HTA readiness lags, it now affects regulatory timelines as well, since JCA submission must run in parallel with the MAA. This shift naturally pulls clinical and medical teams into earlier alignment around relative effectiveness.
Where Organizations Struggle Most
We frequently see companies with brilliant science and strong regulatory plans struggle because their organization wasn’t structured for parallel evidence expectations.
Common signs include:
- Clinical teams designing trials with regulatory-driven endpoints that HTA bodies don’t value.
- Market access teams discovering population and/or comparator misalignment after trial design are locked.
- Medical and HEOR teams working on evidence narratives misaligned with regulatory strategy.
- Regulatory teams preparing MAA materials without considering JCA implications, or missing opportunities where JCA-required evidence could strengthen the MAA or support ODD maintenance.
- Senior leadership assuming HTA can be “handled later.”
These issues can arise even when each function executes well, simply because the work isn’t connected at the points where it needs to be.
The New Operating Model
Being “HTA-ready” means adopting a model where decision-making crosses functions naturally. It means treating evidence as an asset that evolves throughout the entire development program, not as a series of siloed deliverables. It means bringing the right perspectives to the table early to make the process stronger.
The companies who do this well have:
- An integrated clinical development plan that includes clinical evidence needs beyond regulatory approval
- Clear governance for parallel MAA + JCA
- Early involvement from access, HEOR, and RWE experts
- A medical office that bridges strategy and science
- Biostatistical support integrated into early planning
And, importantly, leadership that understands how HTA shapes decisions across the development program.
Why This Matters Now More Than Ever
The speed of innovation, especially in oncology and advanced therapeutics, means the margin for error is shrinking. The cost of misalignment is higher. And organizations increasingly need to act in a coordinated way.
We help biotechs build these capabilities by simplifying how teams make decisions together and by aligning evidence generation with business objectives.
When an organization is HTA-ready, it enters Europe with clarity about what it needs to do and why.
Make sure that’s you.
Related reading
Explore the guide: EU HTA Regulation guide
Continue reading: What the EU HTA Regulation means for biotechs
